InSite Vision Announces Patent Issuance on DuraSite® 2 Ophthalmic Drug Delivery System

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,501,800 on the Company’s DuraSite® 2 next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. This patent will provide utility/composition of matter protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC